The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer: a multicenter retrospective review

BackgroundThe ADAURA trial demonstrated an overall survival benefit with adjuvant osimertinib in epidermal growth factor receptor-mutant (EGFR-mut) non-small cell lung cancer (NSCLC). As only 50% of patients underwent a preoperative brain MRI scan and PET-CT rates were not reported, concerns were raised that suboptimal staging could have led to the inclusion of patients with metastatic disease. There is, however, limited…